By Michael Dabaie

Cytokinetics Inc. (CYTK) shares were up 15% to $9.82 in heavier-than-average volume Wednesday.

Amgen (AMGN), Cytokinetics Inc. and Servier said earlier a data monitoring committee recommended the Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure continue without changes.

Omecamtiv mecarbil is being developed under a collaboration between Amgen and Cytokinetics, with funding and strategic support from Servier.

Amgen shares were down 0.7% to $190.20.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

March 20, 2019 13:09 ET (17:09 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Cytokinetics Charts.
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Cytokinetics Charts.